New Russian COVID-19 Vaccine Convasel Effective Against ‘Stealth Omicron’, FMBA Head Says
© AP Photo / David GoldmanIn this Tuesday, Dec. 15, 2020 file photo, a droplet falls from a syringe after a health care worker was injected with the Pfizer-BioNTech COVID-19 vaccine at a hospital in Providence, R.I.
© AP Photo / David Goldman
MOSCOW (Sputnik) - The Russian vaccine Convasel will be effective against the BA.2 COVID-19 subvariant, known as "stealth Omicron," the head of the Federal Medical-Biological Agency (FMBA), Veronika Skvortsova, said on Saturday.
The Russian Health Ministry registered FMBA's Convasel vaccine on Friday.
"Stealth Omicron [BA.2], which has already taken over BA.1 Omicron variant in Moscow, differs by 28 mutations. These mutations are mainly found in the S-protein and in non-structural proteins, they do not affect the N-protein in those blocks that are used for the vaccine, so the vaccine will be effective, and we are already seeing this now," Skvortsova told Rossiya 24 broadcaster.
Sputnik V is Russia's and the world's pioneer COVID-19 vaccine, registered in August 2020. The two-dose vaccine has a single-dose version, Sputnik Light, and a version for teenagers, Sputnik M. Russia also produces three other COVID-19 vaccines, including Covivac, EpiVacCorona and EpiVacCorona N.